Ixazomib + Pomalidomide + Dexamethasone In MM

Inclusion Criteria: * Patients with relapsed and relapsed refractory myeloma may be eligible for this trial of they meet all the following entry criteria. * Previously diagnosed with MM based on standard IMWG criteria and currently requires treatment. * Patient has given voluntary written informed consent before performance of any study-related procedures not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care * Patient had received at least two previous therapies OR received 1 prior line of therapy if previously treated with an IMiD plus a proteasome inhibitor and has demonstrated disease progression on or within 60 days of completion of the last therapy * Patient has measurable disease defined as at least one of the following according to Standard Diagnostic Criteria (Rajkumar 2014): * Serum IgG, IgA, or IgM M-protein ≥ 0.5 g/dL, or * Serum IgD M-protein ≥ 0.05 g/dL, or * Urine M protein ≥200 mg/24 hours or * Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (\<0.26 or \>1.65) * Screening Laboratory evaluations within the following parameters * Absolute neutrophil count (ANC) ≥ 1,000 cells/dL (1.0 x 109/L) (Growth factors cannot be used more recently than 14 days prior to initiation of therapy) * Platelet count ≥ 75,000 cells/dL (75 x 109/L) (without transfusions required during the 14 days pr…